Cumulative Index 1989

Volume 18

March	MANAGEMENT OF INFLAMMATORY BOWEL DISEASE, pages 1–162
June	MOTILITY DISORDERS, pages 163–466
September	MALABSORPTION AND NUTRITIONAL STATUS AND SUPPORT, pages 467–670
December	GASTROINTESTINAL ENDOCRINOLOGY, pages 671–950

Note: Page numbers of article titles are in **boldface** type.

Abscess, in Crohn's disease, 112–113
  in inflammatory bowel disease, 55
Absorption, of nutrients, normal, 468–471
Acetylcholine, in small intestine motor activity, 386
Achalasia, **223–256**
  aperistalsis in, 228
  carcinoma in, 238–239
  causes of, 223
  chest pain in, 265
  cholecystokinin and, 227–228
  clinical features of, 224–226
    in malignancy, 234–235
  complications of, 237–239
  cricopharyngeal, 213
  denervation hypersensitivity in, 227
  diagnosis of, 229–234
    in malignancy, 235
  endoscopy in, 233–234
  epidemiology of, 224
  epiphrenic diverticuli in, 238
  esophagitis in, 237
  impaired emptying in, 228–229
  in Chagas' disease, 236
  in familial adrenal insufficiency, 237
  in intestinal pseudo-obstruction, 236–237
  malignancy-induced, 234–236
  manometry in, 231–233
  neural damage in, 226–229
  pathology of, 226–227
  pathophysiology of, 227–229, 234
  postvagotomy, 237
  radiography in, 229–231
  secondary, 234–237
  treatment of, 239–250
    bougienage, 241
    esophagomyotomy, 247–250
    in malignancy, 235
    pharmacologic, 240–241
    pneumatic dilatation, 241–247
  vigorous, 231–232
Acid perfusion test, in gastroesophageal reflux, 298–299
ACTH (adrenocorticotropic hormone), in ulcerative colitis, 22–24
Adenocarcinoma, in inflammatory bowel disease, 89
  of esophagus, Barrett's esophagus and, 347–351
Adenoma, in inflammatory bowel disease, 89
Adrenal insufficiency, familial, achalasia in, 237
Adrenocorticotropic hormone (ACTH), in ulcerative colitis, 21–24
Alcohol, chronic pancreatitis and, 556
Allison procedure, in gastroesophageal reflux, 306
Amino acids, branched-chain, in liver disease treatment, 629–635
  deficiency of, in glucagonoma, 833–834
  normal absorption of, 469–470
4-Aminosalicylic acid, in inflammatory bowel disease, 36–38

5-Aminosalicylic acid, as sulfasalazine metabolite, 4–7
in inflammatory bowel disease, 35–36
intolerance to, 47
oral administration of, 43–47
coated forms of, 45, 47
Amyloidosis, small intestine motility disorders in, 412, 414
Amyotrophic lateral sclerosis, esophageal motility disorders in, 215
Anemia, in chronic pancreatitis, 555
in fulminating colitis, 76
in glucagonoma, 835
in sulfasalazine therapy, 11
Angelchik prosthesis, in gastroesophageal reflux, 308
Angina, microvascular, esophageal disorders and, 265–266
Angiography, in carcinoid syndrome treatment, 886
Anorexia, cholecystokinin and, 769
Antacids, in gastric acid hypersecretion, 855
in gastroesophageal reflux, 302
Anti-reflux surgery, 306–308, 328–331
Antibiotics, in inflammatory bowel disease, **51–56**. See also *Sulfasalazine*.
abscess in, 55
antimycobacterial, 53–54
broad-spectrum, 54
fistulae in, 55
nonabsorbable, 53
perioperative, 118
relapsed, 54–55
Anticholinergic agents, in gastric acid hypersecretion, 851–852
in gastroesophageal reflux, 305
Antilymphocyte serum, in inflammatory bowel disease, 58
Antimycobacterial drugs, in inflammatory bowel disease, 53–54
Apnea, in gastroesophageal reflux, 323–325
Appendix, carcinoid tumor of, 866
Appetite. See *Cholecystokinin, actions of, on satiety*.
Arachidonic acid metabolism, sulfasalazine effects on, 4–7
Argyrophil carcinoid tumors, gastric, 683–684
of stomach, in MEN syndrome, 687–688
Artificial enteric sphincters, in short bowel syndrome, 609–611
ASA. See *Aminosalicylic acid*.
Asacol (aminosalicylic acid), in inflammatory bowel disease, 45, 47
Autocrine growth factors, in cancer growth, 785–786
Autoimmune disease, hypoglycemia in, 841
Autonomic neuropathy, small intestine motility disorders in, 414
Azaserine, carcinogenesis and, 779
Azathioprine, in inflammatory bowel disease, 58–68
dosage of, 59
toxicity of, 59
Azodisalicylate (olsalazine), in inflammatory bowel disease, 44–47
Azulfidine. See *Sulfasalazine*.

Bacterial toxins, small intestine motility disorders and, 411
Balsalazide, in inflammatory bowel disease, 44
Barrett's esophagus, **339–357**
adenocarcinoma and, 347–351
clinical presentation of, 341–342
definition of, 339–340
diagnosis of, 345–347, 351–352
etiology of, 340–341
gastroesophageal reflux and, 283–284
manometry in, 342–345
occurrence of, 341–342
pathogenesis of, 340–341
pathology of, 348–351
treatment of, 352–354
Belsey Mark IV procedure, in gastroesophageal reflux, 307
Bernstein acid perfusion test, in gastroesophageal reflux, 298–299
Betamethasone, in ulcerative colitis, 25
Bethanechol, 439
in esophageal spasm evaluation, 263
in gastroesophageal reflux, 305, 320, 443–444
Bile salts, in ileectomy/colectomy therapy, 506–507
malabsorption of, after Crohn's disease surgery, 123
Biliary tract, motility disorders of, **425–435**
classification of, 431
clinical evaluation of, 430–431
evaluation of, 427–430
therapy for, 431–432
normal function of, 426–427
Bleeding, in Crohn's disease, 113–114
in inflammatory bowel disease, 569
Blood dyscrasia, in inflammatory bowel disease therapy, with sulfasalazine, 11
Bombesin, actions of, 708–709
cancer growth and, 780–781, 786
carcinogenesis and, 780
distribution of, 708
structure of, 707
Bone marrow depression, in inflammatory bowel disease therapy with immunosuppressive agents, 66
Bougienage, in achalasia, 241
in esophageal pain, 269
Bowel. See *Intestine*.

Bowel rest, in inflammatory bowel disease, 142–146
Brain disease, esophageal motility disorders in, 215
small intestine motility disorders in, 415–416
Breath tests, in malabsorption identification, 478–479
Brooke ileostomy, with proctocolectomy, in ulcerative colitis, 100–101
Browne-McHardy dilator, in achalasia, 242
Budesonide, in ulcerative colitis, 26
Bulbar palsy, chronic progressive, esophageal motility disorders in, 215
Bulimia, cholecystokinin role in, 750–752, 769
Busulfan, in inflammatory bowel disease, 58

Caffeine, gastroesophageal reflux and, 288
Calcitonin gene-related peptide, 170, 172, 713–714
Calcium, low serum levels of, 473
normal absorption of, 470–471
Calcium channel blockers, in achalasia, 240–241
in esophageal pain, 267–269
Caloric requirements, in acute pancreatitis, 533–535
Campylobacter, Barrett's esophagus and, 341
Cancer, growth of, peptides in. See under *Peptide(s)*.
risk of, in inflammatory bowel disease, **83–97**
Capsaicin, 167
Carbohydrates, in acute pancreatitis, 535–536
Carcinogenesis, peptides and, 778–780
Carcinoid syndrome, 684, 880–885
atypical, 870
classical, 870
clinical features of, 880
diarrhea in, 881
flushing in, 881–884
differential diagnosis of, 882, 884–885
octreotide in, 909
peptide levels in, 880–882
provocative tests in, 882–884
serotonin levels in, 880, 888–889
small intestine motility disorders in, 418
Carcinoid tumors, 680, 682, **865–896**
age distribution of, 872
angiography of, 875
argentaffin and, 870
argyrophil, 683–684
biochemical studies of, 873–874
chemicals secreted by, 870, 872
classification of, 870
computed tomography of, 875
definition of, 870, 872
development of, peptides in, 778
diagnosis of, 873–880
distribution of, 866–867, 870–872
foregut, 870
growth hormone releasing hormone type of, 908
growth of, 889
hindgut, 870
incidence of, 866–872
localization of, 874–880
magnetic resonance imaging of, 875
markers for, 867, 870
MEN–1 with, 870
metaiodobenzylguanidine scintigraphy in, 875–880
metastasis from, treatment of, 889
mid-gut, 870
natural history of, 872–873
of appendix, 866
of stomach, in MEN syndrome, 687–688
prognosis of, 885–886
symptoms of, 870
treatment of, metastatic, 889
radiotherapy in, 890–891
SMS 201–995 in, 886–890
surgical, 886
Carcinoma, esophageal, Barrett's esophagus and, 351–352
in achalasia, 238–239
islet cell. See *Islet cell carcinoma*.
Carotene, low serum levels of, in malabsorption, 472
CCK. See *Cholecystokinin*.
Celiac disease, steatorrhea in, 500–502
Cerebrovascular accident, esophageal motility disorders in, 213–215
Cerulein, cancer growth and, 780–781, 783
carcinogenesis and, 780
Chagas' disease, achalasia in, 236
Chalasia of infancy, 287
Chemotherapy, gastric acid hypersecretion management in, 857
in islet cell carcinoma, 924–926
combination, 924–926
metastatic, 826
single agent, 924–926
Chest pain, in esophageal motility disorders, **257–273**
achalasia, 265
diagnosis of, 266
heartburn, 258–259
microvascular angina, 265–266
nerve supply and, 257
nutcracker esophagus, 264–265
odynophagia, 259–260
spasm, 262–264
spontaneous, 260–262
treatment of, 266–270

Chlorambucil, in inflammatory bowel disease, 58
Chlorozotocin, in islet cell carcinoma, 926
Cholangiocarcinoma, peptides effects on, 780–781, 783
Cholecystitis, acalculous, total parenteral nutrition-associated, 658–660
Cholecystokinin, actions of, 699–700, **735–756**, 736
on gallbladder, 737–740
on gastric emptying, 363, 740–743
on hyperglycemia reduction, 746–749
on insulin secretion, 743–746
on pancreatic exocrine secretion, 749
on satiety, 750–752, **757–775**
anorexia and, 769
behavioral studies in, 764–765
bulimia and, 750–752, 769
central nervous system control in, 757–759
endogenous CCK and, 763–764
human studies in, 765–767
measurement of blood levels in, 764
obesity and, 767–769
peripheral control in, 759–760
physiologic role in, 761–765
receptor studies in, 762–763
therapeutic implications of, 767–769
antagonists to, 762
bioassay for, 736–737
blood level measurement of, 764
cancer growth and, 780–781
receptors activity in, 783
carcinogenesis and, 779–780
distribution of, 698, 735
in central nervous system, 758–759
in biliary tract motility disorders, 429
large molecular forms of, 699
nausea induced by, 765
receptors for, 760, 762–763
cancer growth and, 783
tachyphylaxis in, 768
release of, 698–699, 763–764, 766–767
small molecular forms of, 699
structure of, 697–698, 735–736
toxicity of, 768–769
trypsin inhibition of, 763–764
vasopressin release and, 765
Cholelithiasis, after Crohn's disease surgery, 123–124
Cholesterol levels, in fulminating colitis, 76–77
Cholestyramine, in steatorrhea, 495
Cholinergic agonists, in gastroesophageal reflux, 305
Chromium deficiency, in inflammatory bowel disease, 583
Chromogranins, as tumor markers for carcinoid, 867
Chymotrypsin, cholecystokinin release and, 766
Cimetidine, in gastric acid hypersecretion, 849–850, 856
in jejunostomy, 507
Cineradiography, in swallowing assessment, 204–209
Cirrhosis, alcoholic pancreatitis and, 556
energy metabolism in, 626–628
nitrogen metabolism in, 626–628
protein degradation in, 626
Cisapride, 441–442
in constipation, 451–452
in gastroesophageal reflux, 306, 320, 445–447
in gastroparesis, 448–449
in small intestinal motility disorders, 449–450
Claversal (aminosalicylic acid), in inflammatory bowel disease, 47
Clostridium difficile, in inflammatory bowel disease, antibiotics for, 52–53
Cobalamin, normal absorption of, 471
Colectomy, in Crohn's colitis, with anastomosis, 122
with mucosal proctectomy and ileoanal anastomosis, 122
in fulminant colitis, 79–80
in inflammatory bowel disease, cancer risk and, 91–94
in ulcerative colitis, versus corticosteroid treatment, 27
with ileal pouch formation and sphincter anastomosis, 104–107
with ileorectal anastomosis, 101–102
Colitis, collagenous, sulfasalazine in, 9
Crohn's. See *Crohn's colitis*.
fulminant. See *Fulminant colitis*.
granulomatous. See *Crohn's colitis*.
inactive, versus dysplasia, 86
postdysenteric, sulfasalazine in, 9
quiescent, versus dysplasia, 86
radiation-associated, sulfasalazine in, 9
ulcerative. See *Ulcerative colitis*.
Colon, cancer of, autocrine growth factors in, 785–786
hormone receptors in, 782, 784–785
inflammatory bowel disease and, **83–97**
polyamine levels in, 785
carcinogenesis in, peptides and, 778–779
motility disorders of, dietary factors in, 517–519
prokinetic agents in, 450–452
resection of, steatorrhea in, 504
Colonoscopy, in inflammatory bowel disease, cancer risk and, 93–94
Constipation, prokinetic agents in, 450–452
Copper deficiency, in chronic pancreatitis, 553–554

Corticosteroids, in inflammatory bowel disease, **21–34**
absorption of, 30
chronic, 28
Crohn's disease, **28–31**
foam application of, 24–25
fulminating colitis, 77
in children, 31
in pregnancy, 30
maintenance regimen in, 28
mild, 26–27
moderate, 27
proctitis, 26
prognosis and, 28
severe, 27
topical administration of, 24–26
types of, 22–24
versus nutritional therapy, 139
with immunosuppressive agents, 60–62, 64
Cortisone, in ulcerative colitis, 22
Cotrimoxazole, in inflammatory bowel disease, 54–55
CR1409, cancer growth and, 780–781
Cricopharyngeal achalasia, 213
Cricopharyngeal hypertension, 212
Cricopharyngeal hypotonia, 212–213
Cricopharyngeal myotomy, in esophageal motility disorders, 217
Crohn's colitis, aminosalicylate enemas in, 41
colectomy in, 101–101
with ileorectal anastomosis, 101–102
immunosuppressive agents in, 62
recurrence of, after surgery, 124–125
surgery for, 119–122
total parenteral nutrition in, 131
vancomycin in, 53
Crohn's disease, abscess in, 112–113
antibiotics in, 54–55
nonabsorbable, 53
perioperative, 118
antimycobacterial drugs in, 53–54
bleeding in, 113–114
corticosteroids in, **28–31**
versus nutritional therapy, 139
duodenal, surgery for, 120
elemental diet therapy in, 133, 136, 138–145
fistula in, 112–113
repair of, 120
growth failure in, 570
ileocolic, surgery for, 119–121
recurrence after, 124
immunologic factors in, 146–148
immunosuppressive agents in, 57–63, 65–68
in children, growth failure in, 134–138
malnutrition in, 129–133
metronidazole in, 52
obstruction in, 113
perforation in, 112–113
recurrence of, after surgery, 124–125
refractory, nutritional therapy in, 149
remission of, nutritional therapy during, 141
sulfasalazine in, 8–9
action of, 4
metabolism of, 3
surgery in, **111–128**
acute emergency, 114
as growth failure therapy, 134, 136
bowel resection, 115–116
bypass, 115
complications of, 123–124
duodenal, 120
enterostomy, 116
for intractability, 114
gastrojejunostomy, 120
ileocolic, 119–121
recurrence after, 124
incidence of, 111–112
indications for, 112–114, 120–121
mortality in, 122–123
preparation for, 117–119
principles of, 114–115
procedures for, 115–117
proctocolectomy, 100
recurrence after, 124–125
strictureplasty, 116–117
total parenteral nutrition in, 131, 133, 572–576
urinary tract complications in, 118
vitamin deficiency in, 580
weight loss in, 579
Cushing's syndrome, octreotide in, 908–909
Cyclosporin, in inflammatory bowel disease, 58
Cystic fibrosis, steatorrhea in, dietary treatment of, 498–500
Cytoprotective agents, in gastroesophageal reflux, 302

Dacarbazine, in glucagonoma, 837
Deglutition. See *Swallowing.*
Deglutitive inhibition, 190, 204
Dermatitis, in glucagonoma, 832–833
Dermatitis herpetiformis, in gluten enteropathy, 502
Dermatomyositis, esophageal motility disorders in, 215–216
small intestine motility disorders in, 412
Diabetes mellitus, small intestine motility disorders in, 413–414
weight loss and, 548–549
Diarrhea. See also *Crohn's disease*; *Ulcerative colitis.*
after Crohn's disease surgery, 123

Diarrhea *(Continued)*
in carcinoid syndrome, 880–881
treatment of, 888
in inflammatory bowel disease, 131, 569
in malabsorption, 467
in short bowel syndrome, 593
in sulfasalazine therapy, 12
in VIPoma, octreotide in, 905–906
small intestine motor activity in, 397–398, 417
steatorrhea with, 485–486
Diazoxide, in insulinoma, 843
Dibutyryl cyclic guanosine monophosphate, as cholecystokinin antagonist, 762
Diet. See *Nutrition.*
Dietary fiber, colonic function and, 517–519
in chronic pancreatitis, 560–561
in irritable bowel syndrome, 519–521
Diltiazem, in achalasia, 240
in esophageal pain, 269
5-(Dimethyltriazeno)imidazole-4-carboxamide (DTIC), in islet cell carcinoma, 925–926
Dipentum (olsalazine), in inflammatory bowel disease, 44–47
Diverticulum, epiphrenic, in achalasia, 238
pharyngoesophageal (Zenker's), 213
Domperidone, 441
in gastroesophageal reflux, 306, 445
in gastroparesis, 448–449
Dopamine antagonists, in gastroesophageal reflux, 305–306
Doxorubicin, in islet cell carcinoma, 925, 927
Drugs, esophageal injury by, 259–260
small intestine motility disorders induced by, 415
DTIC, in islet cell carcinoma, 925–926
Duodenum, Crohn's disease of, surgery for, 120
MEN effects on, 686–687
motor activity of, 361–362
Dysautonomia, small intestine motility disorders in, 415
Dysphagia. See *Esophagus, motility disorders of.*
Dysplasia, in inflammatory bowel disease, **83–97**
cancer risk and, 84–85
classification of, 85–92
indefinite identification of, 86, 89
low-grade versus high-grade, 91–92
reversal of, 89, 91
Dystrophia myotonica, small intestine motility disorders in, 412

Eating disorders. See *Cholecystokinin, actions of, on satiety.*
Edrophonium, in esophageal spasm evaluation, 262
Eicosanoids, in inflammatory bowel disease, 148
Electrolytes, in acute pancreatitis, 538
Eledoisin, 167
Elemental diet, in Crohn's disease, 133, 136, 138–145
Embolization, in islet cell carcinoma treatment, 927–928
Emesis. See *Vomiting.*
Endocrine cells, classification of, 672–657
cytology of, 671–672
embryology of, 680
Endocrine tumors. See also *Carcinoid tumors; Islet cell tumors.*
argyrophil, of stomach, in MEN syndrome, 687–688
ectopic hormone production by, 675, 677–679
growth of, octreotide and, 910–912
gut, 679–684
hyperfunctional syndromes and, 677
malignant potential of, 675–679
mixed cell types in, 679, 682
pancreatic, 675–679
pancreatic polypeptide levels in, 711–712
Endocrinology. See also *Cholecystokinin; Pancreas; Peptide(s).*
cancer and, autocrine growth factors in, 785–786
carcinogenesis in, 778–780
hormone receptors in, 782–785
tumor growth in, 780–782
in gastric acid hypersecretion management, **847–863**
medical, 848–855
in acute condition, 855–859
surgical, 859–861
in Zollinger-Ellison syndrome management, **847–863**
medical, 848–855
in acute condition, 855–859
surgical, 859–861
systems of, **671–693**
classification of, 672–675
cytology of, 671–672
tumors of. See *Endocrine tumors; Islet cell tumors.*
Endoscopic retrograde pancreatography, in malabsorption identification, 479
Endoscopy, in achalasia, 233–234
in Barrett's esophagus, 345–347
in gastroesophageal reflux, 295
Enema, in inflammatory bowel disease treatment, corticosteroids in, 24–27
salicylates in, **35–42**
duration of, 38–40
maintenance regimen for, 40–41
relapse rate, 39–41

with sulfasalazine, 38
Enkephalins, 166–167
Enprostil, cancer growth and, 782–783
Enteral diet therapy, in inflammatory bowel disease, 133
Enteric nervous system, small intestine motility disorders and, 416
small intestine motor activity and, 384–386, 391–393
Enterogastrone, GIP as, 706
Enteroglucagons, 707
Enterostomy, in Crohn's disease, 116
in small intestine motility disorders, 418
Epidermal growth factor, cancer growth and, 785–786
carcinogenesis and, 779–780
Epilepsy, small intestine motility disorders in, 416
Ergonovine, in esophageal spasm evaluation, 263–264
Erythema, necrolytic migratory, in glucagonoma, 831–832
Esophageal clearance, gastroesophageal reflux and, 279–280
Esophageal sphincter, lower, adaptive pressure response of, 278–279
anatomy of, 181
function of, 190–191
in achalasia, 226–229
innervation of, 181–185
reflux disease and, 276–279, 283–286
tonic pressure of, 276–278
transient relaxation of, 284–286
upper, anatomy of, 180, 199
disorders of, 212–213
function of, 186–187
physiology of, 200–204
Esophagitis, in achalasia, 237
in gastroesophageal reflux, 321–323
treatment of, 266–267
Esophagography, in gastroesophageal reflux, 294–295
Esophagomyotomy, in achalasia, 247–248
Esophagoscopy, in swallowing assessment, 211–212
Esophagus, adenocarcinoma of, Barrett's esophagus and, 347–351
anatomy of, 179–181, 199–200
Barrett's. See *Barrett's esophagus*.
carcinoma of, Barrett's esophagus and, 351–352
in achalasia, 238–239
chemical injury of, 259–260
disease of, gastric acid hypersecretion management in, 858
innervation of, 181–185
motility disorders of, **195–222**
achalasia. See *Achalasia*.
anatomical considerations in, 195–200
chest pain in, **257–273**
cineradiography in, 204–209
cricopharyngeal achalasia, 213
cricopharyngeal hypertension, 212
cricopharyngeal hypotonia, 212–213
diagnosis of, 229–234
endoscopy in, 233–234
esophagoscopy in, 211–212
evaluation of, 204–212
in cerebrovascular accident, 213–215
in familial adrenal insufficiency, 237
in familial dysautonomia, 213
in primary muscle disease, 215–216
malignancy-induced, 234–236
manometry in, 209–211, 231–233
neurologic, 213–215
pharyngoesophageal diverticulum, 213
physiology of, 200–204
postvagotomy, 237
radiography in, 229–231
symptoms of, 204
treatment of, 216–217, 239–250, 267–270
motor function of, **179–194**, 200–204
anatomy and, 179–181, 199–200
coordination of, 185–191
deglutitive inhibition, 190, 204
esophageal body in, 187–190
innervation and, 181–185
lower sphincter in, 190–191
myenteric nerve plexus and, 183–185
primary peristalsis, 185
secondary peristalsis, 185–186
swallowing center and, 181–182
upper sphincter in, 186–187
nutcracker, 264–265
perforation of, in dilatation, 246–247
pH monitoring of, 299–300
physiology of, 200–204
pneumatic dilatation of, in achalasia, 241–247
reflux into. See *Gastroesophageal reflux disease*.
spasm of, 262–264
Ethambutol, in Crohn's disease, 54
Exercise, gastric emptying and, 368
Extrapyramidal disease, small intestine motility disorders in, 415–416

Familial adrenal insufficiency, achalasia in, 237
Familial dysautonomia, esophageal disorders in, 213
Famotidine, in gastric acid hypersecretion, 851
Fat, in acute pancreatitis, 536–537
normal absorption of, 470
Fatty acid deficiency, in inflammatory bowel disease, 144

Fecal fat, excretion of, in malabsorption identification, 474–475
Fistula, in Crohn's disease, 112–113
repair of, 120
in inflammatory bowel disease, 55
5-Fluorouracil, in islet cell carcinoma, 925–926
Flushing, in carcinoid syndrome, 880–884
appearance of, 882
differential diagnosis of, 882, 884–885
treatment of, 887–888
Fluticasone, in Crohn's disease, 30
Folate deficiency, in malabsorption, 471
Food allergy, irritable bowel syndrome and, 514–516
Food intake. See *Cholecystokinin, actions of, on satiety.*
FOY-305 (gabexate mesilate), cholecystokinin release and, 763–764, 766
Fructose, irritable bowel syndrome and, 515
Fulminant colitis, in inflammatory bowel disease, **73–82**
clinical characteristics of, 74–76
complications of, 77–78
diagnosis of, 77
incidence of, 73–74
laboratory results in, 76–77
pathology of, 78
prognosis of, 80
treatment of, 78–79
Fundoplication, in gastroesophageal reflux, 306–308, 329–331

Gabexate mesilate, cholecystokinin release and, 763–764, 766
Galanin, 169–170
actions of, 718
distribution of, 718
structure of, 718
Gallbladder, cholecystokinin action on, 699, 737–730
disease of, after Crohn's disease surgery, 123–124
in octreotide therapy, 912
Gas syndromes, postprandial distention and, 521–522
Gastrectomy, gastric acid hypersecretion management after, 857–858
in Zollinger-Ellison syndrome, 859
small intestine motility disorders after, 409
Gastric acid hypersecretion, management of, **847–863**
in short bowel syndrome, 603
medical, 848–859
after gastrinoma resection, 858–859
antacids in, 855
anticholinergic agents in, 851–852
criteria for, 849
during elective surgery, 857
emergency, 855–856
histamine H_{12}-receptor antagonists in, 849–851
in esophageal disease, 858
octreotide in, 855
omeprazole in, 852–855
prostaglandin analogues in, 855
with chemotherapy, 857
with previous partial gastrectomy, 857–858
octreotide in, 903–905
surgical, medical management with, 857–859
parathyroidectomy in, 860–861
parietal cell vagotomy in, 859–860
total gastrectomy in, 859
symptoms of, 847–848
Gastric dumping syndrome, neurotensin in, 713
Gastric emptying, **359–373**
antrum in, 360
cholecystokinin action on, 740–743
duodenum in, 361–362
excessively slow, 369
exercise effects on, 368
fundus in, 359–360
gastroesophageal reflux and, 281, 330–331
lipids and, 363
migrating motor complex in, 367
nausea and, 368–369
nutrient effects on, 362
of solids, 364–366
pepsin in, 365–366
prokinetic agents and, 447–449
pylorus in, 360–361
small intestinal receptor mechanisms and, 362–365
solid-liquid discrimination in, 365–366
stress and, 368
viscosity effects on, 366–369
vomiting and, 368–369
Gastric inhibitory polypeptide, 166
actions of, 706
distribution of, 706
release of, 706
structure of, 705–706
Gastric volume, gastroesophageal reflux and, 280–282
Gastrin, actions of, 702
cancer growth and, 780
receptors activity and, 782–785
carcinogenesis and, 778–779
distribution of, 700
in gastroesophageal reflux, 278
inflammatory bowel disease and, 145
receptors for, antagonists for, 855
cancer growth and, 782–785
release of, 701–702

structure of, 700
Gastrin cells, hyperplasia of, 682–683
Gastrin-releasing peptide, actions of, 708–709
distribution of, 708
structure of, 708
Gastrinoma, 683. See also *Zollinger-Ellison syndrome.*
diagnostic studies in, 821–822
duodenal, 686–687
surgical management of, 813, 817–818
extrapancreatic, 799
in MEN syndrome, 865–867
intra-arterial secretin test in, 799–801
localization of, 798–801
intraoperative, 817
magnetic resonance imaging in, 801
medical management of, 817, 819
metastasis from, 821
chemotherapy in, 826
potential of, 806–807
surgical management of, 824
of stomach, 687
pancreatic, 685–686
pancreatic arteriography in, 799
portal venous sampling in, 799, 821–822
surgical management of, 817–819
medical management with, 858–859
postoperative care in, 858–859
Gastroesophageal reflux disease, acid reflux test in, 299
antacids in, 302
apnea with, 323–325
Barrett's esophagus and, 340–341
barriers to, 276–279
clinical history in, 293–294
cytoprotective agents in, 302
detection of, **293–313**
documentation of, 299–301
endoscopic transmucosal potential difference in, 296
endoscopy in, 295
environmental modifications in, 301–302
esophageal clearance and, 279–280
exertional, 261
functional, 316–320
gastric volume and, 280–282
gastrostomy and, 328
heartburn in, 258–259, 275–276
hiatus hernia and, 282–283
histology of, 295–296
iatrogenic, 288
in pediatric patients, 287, **315–337**
in pregnancy, 287
in scleroderma, 287–288
lower esophageal sphincter and, 276–279, 283–286
manometry in, 297
mechanisms of, 282–286
motility evaluation in, 296–298
mucosal evaluation in, 294–296
neurologic, 328
pathogenic, 320–323
pathophysiology of, **275–291**
pH monitoring in, 299–300
pulmonary disease and, 325–328
radiography in, 294–295
reflux scan in, 300–301
secondary (neurologic), 328
symptoms of, 275–276, 298–299
systemic therapy in, 302–306
transit scintigraphy in, 297–298
treatment of, **293–313**
in infants, 319–320
prokinetic agents in, 442–447
Gastrojejunostomy, in Crohn's disease, 120
Gastroparesis, 369
prokinetic agents in, 447–449
Gastrostomy, gastroesophageal reflux and, 328
GHRHoma, octreotide in, 908
Gila monster venom peptide, 166
GIP. See *Gastric inhibitory polypeptide.*
Glicentin, 707
Glucagon, in motility, 166
Glucagonoma, **831–837**
age distribution of, 832
anemia in, 835
asymptomatic, 836
clinical features of, 832–835
definition of, 831
dermatitis in, 832–833
diagnosis of, 835–836
distribution of, 831
glucose intolerance in, 834–835
hypoaminoacidemia in, 833–834
incidence of, 832
localization of, 837
malignant potential of, 831
metastasis from, chemotherapy in, 826
potential of, 806
surgical management of, 824, 826
size of, 831
surgical management of, 819
symptoms of, 819
thromboembolism in, 835
treatment of, 837
octreotide in, 907–908
weight loss in, 835
Glucagonoma syndrome, 831–832
Glucagons, enteral, 707
Glucose intolerance, in glucagonoma, 834–835
Glucose levels, cholecystokinin effects on, 746–749
Glutamine, in nutritional therapy of inflammatory bowel disease, 145
Gluten enteropathy, dermatitis herpetiformis and, 502
steatorrhea in, 500–502

Granulomatous colitis. See *Crohn's colitis.*
Growth disorders, in chronic pancreatitis, 555
in inflammatory bowel disease, 570
medical therapy in, 134
nutritional therapy in, 133–134, 136, 138
surgical therapy in, 134, 136
Growth factors, in cancer growth, 785–786
Growth hormone releasing factor, 166
Growth hormone releasing hormone, tumors secreting, octreotide in, 908
GRP (gastrin-releasing peptide), 708–709

Haloperidol, in constipation, 451
Harris-Benedict equation, 534
Heartburn, 258–259, 275–276, 293–294
Heller myotomy, modified, in achalasia, 247–248
Helodermin, 166
Hepatic artery embolization, in islet cell carcinoma metastasis, 927–928
Hepatic encephalopathy, branched-chain amino acids for, 632–636
Hepatitis, alcoholic, parenteral amino acid supplementation in, 629
Hepatobiliary abnormalities, in total parenteral nutrition, **645–666**
in adults, 651–658
biochemical findings in, 649–650
clinical presentation in, 649–650
management of, 657–658
morphologic, 652–654
pathogenesis of, 654–657
prevention of, 657–658
in infants, 646–650
morphologic features of, 648–649
pathogenesis of, 649–650
treatment of, 650
Hiatus hernia, gastroesophageal reflux and, 282–283
Hill procedure, in gastroesophageal reflux, 307
Histamine H_{12} antagonists, in gastric acid hypersecretion, 849–851, 856–857
in gastroesophageal reflux, 303–304
Hollow visceral myopathy, small intestine motility disorders in, 412–413
Hunger, control of. See *Cholecystokinin, actions of, on satiety.*
Huntington's chorea, esophageal motility disorders in, 215
Hurst-Tucker dilator, in achalasia, 242
Hydralazine, in esophageal pain, 269
Hydrocortisone, in ulcerative colitis, 22–25, 27
Hydroeicosatetranoic acids, formation of, sulfasalazine effects on, 6
Hydroureter, in Crohn's disease, 118
5-Hydroxyindolacetic acid, in carcinoid tumors, 873–874
5-Hydroxytryptophan, in carcinoid tumors, 873–874
Hyoscyamine, in esophageal pain, 269
Hypergastrinemia, cancer growth and, 778–779
octreotide in, 905
Hyperglucagonemia, in glucagonoma, 836
Hyperglycemia, cholecystokinin effects on, 746–749
Hyperinsulinemia, diagnostic procedures in, 798
neonatal (nesidioblastosis), 815–816
Hyperinsulinemic hypoglycemia, 816
Hyperoxaluria, in steatorrhea, 489
Hyperparathyroidism, in MEN–1 syndrome, 820, 822
Hypersensitivity, in inflammatory bowel disease therapy, with immunosuppressive agents, 66–67
with sulfasalazine, 10–11
small intestine motility disorders in, 417–418
Hypoalbuminemia, in fulminating colitis, 76
Hypoaminoacidemia, in glucagonoma, 833–834
Hypocalcemia, in acute pancreatitis, 538–539
Hypoglycemia, causes of, 840–841
hyperinsulinemic, 816
in insulinoma, 838
octreotide in, 902–903
Hypokalemia, in fulminating colitis, 77
Hypotension, orthostatic, small intestine motility disorders in, 415
Hypothalamus, appetite control by, 758–759

Ileal resection, steatorrhea in, 503–504
Ileocolic Crohn's disease, surgery for, 119–121
surgery in, recurrence after, 124
Ileocolitis, immunosuppressive agents in, 62
Ileostomy, continent, in Crohn's colitis, 121–122
in ulcerative colitis, 102–104
permanent, in Crohn's colitis, 121
in Crohn's disease, 116
with proctocolectomy, in ulcerative colitis, 100–101
Ileus, postoperative, prokinetic agents in, 449–450
Immune system, incompetence of, in chronic pancreatitis, 555–556
Immunologic effects, of nutritional therapy in inflammatory bowel disease, 146–148

Immunosuppressive activity, of sulfasalazine, 4
Immunosuppressive agents. See also *6-Mercaptopurine*.
in fulminant colitis, 79
in inflammatory bowel disease, **57–71**
Infants, gastroesophageal reflux in, 287
total parenteral nutrition in, hepatic complications in, 646–650
Infection, in Crohn's disease surgery, 123
Inflammatory bowel disease. See also *Crohn's disease*; *Ulcerative colitis*.
cancer risk of, **83–97**
fulminant colitis in, **73–82**
malnutrition in, 129–133
management of, antibiotics in, **51–56**. See *Sulfasalazine*.
corticosteroids in, **21–34**
with immunosuppressive agents, 60–62, 64
immunosuppressive agents in, **57–71**, 60–62, 64
nutritional, **129–144**. See under *Nutrition*.
salicylates in, enema administration of, **35–42**
oral, **43–50**
nutritional depletion in, **567–578**
inadequate oral intake, 567–568
increased gastrointestinal losses, 569
malabsorption in, 568–569
nutritional requirements in, 570
nutritional support in, 570–576
enteral, 570–571
parenteral, 572
total parenteral, 572–576
toxic megacolon in, **73–82**
trace element deficiencies in, **579–587**
Insulin, secretion of, cholecystokinin action on, 743–746
Insulin-like growth factor, cancer growth and, 785
Insulinoma, **837–843**
age distribution of, 837
catecholamine release in, 838
clinical features of, 838
computed tomography of, 794–795
diagnosis of, 839–840
differential diagnosis of, 840–841
distribution of, 814, 838
hypoglycemia in, 838
in MEN syndrome, 685, 820, 822
localization of, 793–798, 841–843
intraoperative, 815
magnetic resonance imaging of, 795
malignant potential of, 838
medical management of, 814, 843
octreotide in, 902–903
metastasis from, potential of, 806–807
surgical management of, 824
neuroglucopenia in, 838
occult, management of, 815
pancreatic arteriography in, 793–795
portal venous sampling in, 795
prevalence of, 837
sex differences in, 837
size of, 838
surgical management of, 813–816, 843
treatment of, 843
ultrasonography in, 795, 797–798
Interferon, in islet cell carcinoma, 927
Intestinal bypass surgery, in Crohn's disease, 115
Intestine, endocrine cells of, 671–675
interpositions in, in short bowel syndrome, 606–608
lengthening procedures for, in short bowel syndrome, 609
obstruction of, in Crohn's disease, 113
physiology of, 589–590
pseudo-obstruction of, achalasia in, 236–237
resection of, absorption in, 591–592
intestinal adaptation in, 592–593
motility in, 590–591
pathophysiology of, 590–591
Ipsalazide, in inflammatory bowel disease, 44
Iron, deficiency of, in chronic pancreatitis, 553
low serum levels of, 474
normal absorption of, 471
Irritable bowel syndrome, colonic motor dysfunction in, 517–519
definition of, 513–514
dietary fiber in, 519–521
dietary history in, 514–515
food allergy and, 514–516
nutritional treatment of, **513–524**
colonic motor dysfunction in, 517–519
dietary history in, 514–515
fiber in, 519–521
food allergy and, 514–516
postprandial distention in, 521–522
small intestine motility in, 416–417
symptoms of, 521–522
Islet cell carcinoma, **923–930**
biologic therapy of, 927
chemotherapy of, 924
combination, 926
single agent, 924–926
incidence of, 923
metastasis from, 923
radiotherapy of, 928
treatment options for, 923–924
vascular occlusion treatment of, 927–928
Islet cell tumors. See also *Islet cell carcinoma*; specific tumor, eg, *Gastrinoma*; *Insulinoma*.
growth hormone releasing hormone, 908

Islet cell tumors *(Continued)*
incidence of, 897
localization of, **793–804**
gastrinoma, 798–801
insulinoma, 793–798
intraoperative, 812–813
medical management of, 807, 898. See also *Octreotide*.
metastatic, chemotherapy in, 826
potential of, 806–807
surgical management of, 823–826
parathormone-type, octreotide in, 910
surgical management of, **805–830**, 898
complications of, 813–814
enucleation in, 813
gastrinoma, 817–819
glucagonoma, 819, 837
goals of, 805–806
in MEN–1 syndrome, 820–823
in metastatic disease, 823–826
in Zollinger-Ellison syndrome, 820–822
insulinoma, 814–816
natural history and, 806–807
nesidioblastosis, 815–816
operative approach in, 810–813
palliative, 807
pancreatic resection in, 813
preoperative preparation for, 807–809
theoretical features of, 806–807
tumor localization in, 812–813
VIPoma, 819–820
Islet cells, types of, 672
Isopropamide, in gastric acid hypersecretion, 851–852
Isosorbide dinitrate, in achalasia, 240

Jejunal resection, steatorrhea in, 503

Kassinin, 167
Kock pouch, in Crohn's colitis, 121–122
in ulcerative colitis, 102–104

L364,718, as cholecystokinin antagonist, 762
Lactation, sulfasalazine use in, 9
Lactose, labeled, in malabsorption breath test, 478
Lausanne-Santa Monica classification, of endocrine cells, 672–674
Leukocyte interferon, in islet cell carcinoma, 927
Leukotrienes, formation of, sulfasalazine effects on, 6
Liver disorders. See also *Cirrhosis*.
chronic, steatonecrosis and, 653–654
in inflammatory bowel disease therapy, with immunosuppressive agents, 66
with sulfasalazine, 11–12
metastatic, embolization treatment of, 927–928
from carcinoid tumor, 875, 878, 880
treatment of, 886
nitrogen balance in, 626–629
nutritional assessment in, 621
nutritional therapy in, **619–643**
alpha keto acids, 636
amino acid supplementation, 629–636
casein protein, 637
vegetable protein, 636–637
protein calorie malnutrition in, etiology of, 621–626
prevalence of, 620–622
prognosis for, 622–623
total parenteral nutrition in. See under *Hepatobiliary abnormalities*.
Low-fat diet, in steatorrhea management, 488–490, 505–506
Lymphoma, in immunosuppressive therapy, 67

Magnesium deficiency, in chronic pancreatitis, 553
Malabsorption, causes of, 468–469
definition of, 467
in inflammatory bowel disease, 568–569
patient evaluation in, **467–483**
signs and symptoms of, 467–468
tests for, 471–481
Male infertility, in sulfasalazine therapy, 12
Malignancy. See also *Adenocarcinoma*; *Cancer*; *Carcinoma*.
achalasia in, 234–235
Malnutrition, growth disorders caused by, 570
in alcoholics without liver disease, 619
in chronic liver disease, 621
in chronic pancreatitis, 554–555
clinical manifestations of, 544–554
in inflammatory bowel disease, 129–133, 567–570. See also *Inflammatory bowel disease, nutritional depletion in*.
protein calorie, in liver disease, etiology of, 621–626
prevalence of, 620–622
prognosis for, 622–623
Manometry, in Barrett's esophagus, 342–345
in biliary tract motility disorders, 427–429
in esophageal motility disorders, 231–233
in gastroesophageal reflux, 297
in swallowing assessment, 209–211
Mecholyl test, in achalasia, 227
Medium-chain triglycerides, in steatorrhea, 491–494

Megacolon, toxic. See *Toxic megacolon.*
MEN. See *Multiple endocrine neoplasia syndrome.*
Mental retardation, gastroesophageal reflux in, 328
6-Mercaptopurine, in inflammatory bowel disease, **57–71**
dosage of, 59
in abscess treatment, 55
toxicity of, 59
Mesalamine/Mesalazine. See *5-Aminosalicylic acid.*
Metaiodobenzylguanidine, in carcinoid tumors, diagnosis of, 875–880
treatment of, 890–891
Metastasis, from carcinoid tumors, treatment of, 889
from gastrinoma, surgical management of, 824
from glucagonoma, surgical management of, 824, 826
from insulinoma, surgical management of, 824
from islet cell tumors, 806–807
surgical management of, 823–826
from VIPoma, surgical management of, 824, 826
Methotrexate, in inflammatory bowel disease, 58
Methyl prednisolone, in fulminant colitis, 78
Metoclopramide, 439–441
in constipation, 451
in gastroesophageal reflux, 305–306, 320, 444–445
in gastroparesis, 448–449
in small intestinal motility disorders, 449–450
Metronidazole, in fulminant colitis, 79
in inflammatory bowel disease, 52, 54–55
Micronutrients, in steatorrhea, 494–495
Microvascular angina, esophageal disorders and, 265–266
Migrating clustered contractions, of small intestine, 393–394
Migrating motor complex, in gastric emptying, 367
in small intestine, 388–393
Minerals, in pancreatitis, acute, 537–538
chronic, 553–554
Misoprostil, in gastric acid hypersecretion, 855
Molybdenum deficiency, in inflammatory bowel disease, 583–584
Motilin, actions of, 716
distribution of, 716
in small intestine motor activity, 390–391
release of, 716
structure of, 716
Motility disorders, achalasia, **223–256**
Barrett's esophagus. See *Barrett's esophagus.*
chest pain in, **257–273**
gastric emptying and, **359–373**
gastroesophageal reflux, diagnosis/treatment of, **293–313**
in pediatric patient, **315–337**
pathophysiology of, **275–292**
gastroparesis, **359–373**
of biliary tract, **425–435**
of esophagus, motor function and, **179–194**
upper, **195–222**
of small intestine, **405–424**
peptides and, **163–177**
prokinetic agents in, **437–457**
small intestine motor activity and, **375–404**
Mouth, anatomy of, 195
Multiple endocrine neoplasia syndrome, type 1, duodenal pathology in, 686–687
Multiple endocrine neoplasia syndrome (type 1), gastric pathology in, 687–688
insulinoma with, 820, 822
islet cell tumor resection in, 820–823
pancreatic pathology in, 684–686
parathyroidectomy in, 860–861
pathology of, 684–688
VIPoma with, 820–822
Zollinger-Ellison syndrome with, 820–822
Multiple sclerosis, esophageal motility disorders in, 215
small intestine motility disorders in, 416
Muscle disease (myopathy), esophageal motility disorders in, 215–216
small intestine motility disorders and, 412–413
Muscular dystrophy, esophageal motility disorders in, 216
Myasthenia gravis, esophageal motility disorders in, 215
Mycobacteria, in inflammatory bowel disease, antibiotics for, 53–54
Myenteric plexus, in achalasia, 226
of esophagus, 183–185
Myopathy, in carcinoid syndrome, 888
Myotomy, in achalasia, 247–248
in esophageal pain, 270
Myotonic dystrophy, esophageal motility disorders in, 216
small intestine motility disorders in, 412

Nausea, mechanisms of, 368–369
Necrolytic migratory erythema, in glucagonoma, 831–832
Neomucosa, intestinal, in short bowel syndrome, 610–615

Nerves, in gastrointestinal tract, endocrine cells and, 672
Nesidioblastosis, 809
  hypoglycemia in, 841
Neurofibromatosis, small intestine motility disorders in, 414
Neurokinins, 167, 169
  in carcinoid syndrome flushing, 883
Neuropathy, small intestine motility disorders in, 413–416
Neuropeptide Y, 172
  actions of, 711
  distribution of, 709
  release of, 711
  structure of, 709
Neurotensin, actions of, 712–713
  distribution of, 712
  release of, 712
  structure of, 712
Neurotransmitters, in small intestine motor activity, 386–387
  peptide. See *Peptide(s)*.
Nifedipine, in achalasia, 240
  in esophageal pain, 269–270
Nissen procedure, in gastroesophageal reflux, 307, 329
Nitrates, in achalasia, 240
  in esophageal pain, 269
Nitrogen balance, in liver disease, 626–627
Nitrogen mustard, in inflammatory bowel disease, 58
Nitroglycerin, in achalasia, 240
  in esophageal pain, 269
Nizatidine, in gastric acid hypersecretion, 851
Norepinephrine, in small intestine motor activity, 386
NPY (neuropeptide Y), 172, 709, 711
Nutcracker esophagus, 264–265
Nutrition. See also *Total parenteral nutrition*.
  depletion of, in inflammatory bowel disease. See under *Inflammatory bowel disease*.
  in acute pancreatitis. See under *Pancreatitis, acute*.
  in chronic pancreatitis, 560–562
  in inflammatory bowel disease management, **129–155**
    bowel rest and, 143–146
    disease activity and, 138–150
    elemental diets in, 139–141
    formulas for, 131
    immunologic effects of, 146–148
    in children, 133–138
    in growth failure, 133–138
    in steroid dependence, 141–142
    indications for, 131
    intestinal adaptation in, 143–146
    mechanism of action of, 142–150
    of complex cases, 141–142
    overview of, 129–133
    remission maintenance in, 141
    results of, 148–150
  in liver disease, **619–643**
  in short bowel syndrome, **589–601**
  in steatorrhea, 489–495

Obesity, cholecystokinin and, 767–769
Obstruction, intestinal, in Crohn's disease, 113
Octreotide (SMS 201-995), **897–922**
  actions of, 902
  cancer growth and, 784
  development of, 900–901
  in carcinoid syndrome, 886–890, 909
  in Cushing's syndrome, 908–909
  in gastric acid hypersecretion, 855
  in GHRHoma, 908
  in glucagonoma, 837, 907–908
  in insulinoma, 843, 902–903
  in nonfunctioning islet cell tumors, 909–910
  in VIPoma, 905–906
  in Zollinger-Ellison syndrome, 903–905
  pharmacokinetics of, 901
  potency of, 901
  side effects of, 912–913
  structure of, 900–901
  tumor size effects of, 910–912
  unresolved issues of, 913
  versus somatostatin, 899–901
Oculopharyngeal dystrophy, esophageal motility disorders in, 216
Odynophagia, 259–260
Olsalazine, in inflammatory bowel disease, 44–47
Omeprazole, in gastric acid hypersecretion, 852–855, 857
Opioid peptides, 166–167
Oropharyngeal dysphagia. See *Esophagus, motility disorders of*.
Orthostatic hypotension, small intestine motility disorders in, 415
Osteomalacia, steatorrhea and, 486
Oxyntomodulin, 166, 707

Pacing, intestinal, in short bowel syndrome, 611–612
Pain, abdominal, in chronic pancreatitis, 545–546
Pancreas, cancer growth in, 780–781
  cancer of, autocrine growth factors in, 785
  receptor activity in, 783–784
  carcinogenesis in, peptides and, 779–780
  cholecystokinin action on, 743–746

endocrine cells of, 671–675
endocrine tumors of, 675–679
exocrine secretions of, cholecystokinin effects on, 749
insufficiency of, chronic pancreatitis causing, 495–498
MEN effects on, 684–686
Pancreastatin, 717
Pancreatectomy, in islet cell tumor, 813
in nesidioblastosis, 816
Pancreatic enzyme supplements, in chronic pancreatitis, 557–560
Pancreatic juice, drainage of, after islet cell surgery, 814
secretion of, cholecystokinin effects on, 749
Pancreatic polypeptide, 172
actions of, 711–712
distribution of, 709
in small intestine motor activity, 390
release of, 709–710
structure of, 709
Pancreatitis, acute, nutritional support in, **525–542**
caloric requirements, 533–535
carbohydrates, 535–536
electrolytes, 537–538
enteral route of, 530–532
fats, 536–537
impact of, 538
minerals, 537–538
parenteral route of, 532–533
proteins, 535
vitamins, 537–538
Ranson's prognostic criteria in, 534
sepsis and, metabolic similarities between, 525–527
chronic, alcoholic, cirrhosis in, 556
versus nonalcoholic, 554–555
nutritional deficiencies in, **543–565**
clinical manifestations of, 544–554
history of, 554–555
parotid gland enlargement, 544–554
small-bowel function in, 550–551
steatorrhea in, 495–498
treatment of, 556–562
in immunosuppressive therapy of inflammatory bowel disease, 66
Pancreozymin. See *Cholecystokinin.*
Pandysautonomia, small intestine motility disorders in, 415
Para-aminosalicylic acid. See *Aminosalicylic acid.*
Paraneoplastic neuropathy, small intestine motility disorders in, 414–415
Parathormone-type islet cell tumor, octreotide in, 910
Parathyroid disorders, in MEN–1 syndrome, 820, 822
Parathyroidectomy, in Zollinger-Ellison syndrome, 860–861
Parenteral nutrition. See *Total parenteral nutrition.*
Parietal cell vagotomy, in Zollinger-Ellison syndrome, 859–860
Parietal cells, gastrin stimulation of, 702
Parkinson's disease, esophageal motility disorders in, 215
Parotid gland enlargement, in chronic pancreatitis, 555
Pediatric patients. See also *Infants.*
gastroesophageal reflux in, 287, **315–337**
apnea with, 323–325
chronic pulmonary disease and, 325–328
functional type, 316–320
pathogenic, 320–323
secondary (neurologic), 328
surgery in, 328–331
inflammatory bowel disease in, corticosteroids in, 31
immunosuppressive therapy in, 67
nutritional therapy in, 133–134, 136, 138
sulfasalazine in, 9–10
Pentagastrin, cancer growth and, 780
in esophageal spasm evaluation, 264
Pentasa (aminosalicylic acid), in inflammatory bowel disease, 45, 47
Pepsin, in gastric emptying, 365–366
Peptide(s), **695–733**
bombesin, 707–709
calcitonin gene-related, 713–714
cancer growth and, **777–791**
autocrine growth factors and, 785–786
hormone receptors and, 782–785
in carcinogenesis, 778–780
cholecystokinin. See *Cholecystokinin.*
discovery of, 695
enteroglucagons, 707
galanin, 169–170, 718
gastric emptying and, 363
gastric inhibitory polypeptide, 166, 705–706
gastrin. See *Gastrin.*
gastrin-releasing, 707–709
in carcinoid tumors, 867, 870, 882–884
in motility control, **163–177**
action of, 164–166
calcitonin gene-related, 170, 172
galanin, 169–170
location of, 163–164
neurokinin family, 167, 169
neuropeptide family, 172
opioid family, 166–167
pancreatic, 172
secretin family, 166
tachykinin family, 167, 169
vasoactive intestinal peptide family, 166

Peptide(s) *(Continued)*
YY, 172
in small intestine motor activity, 386–387, 390–391
mechanism of action of, 695–697
motilin, 716
neuropeptide Y, 172, 709–712
neurotensin, 712–713
pancreastatin, 717
pancreatic polypeptides, 172, 390, 709–712
peptide histidine-isoleucine, 706–707
secretin, 166, 702–704
somatostatin. See *Somatostatin.*
substance P, 167, 169, 387, 717–718
vasoactive intestinal. See *Vasoactive intestinal peptide.*
YY, 709–712
Peptide histidine-isoleucine, 706–707
Peptide YY, actions of, 711–712
distribution of, 709
release of, 710–711
structure of, 709
Peripheral neuropathy, esophageal motility disorders in, 215
small intestine motility disorders in, 413–415
Peristalsis, in esophagus, 185–190, 201–204
absence of. See *Achalasia.*
in small intestine. See *Small intestine, motor activity of.*
Pharyngoesophageal (Zenker's) diverticulum, 213
Pharynx, anatomy of, 196–198
physiology of, 200–204
Phenylalanine, in cholecystokinin release, 763, 766
PHI (peptide histidine-isoleucine), 706–707
PHI/PHM (peptides), 166
Physalaemin, 167
Pneumatic dilatation, in achalasia, 241–247
in esophageal pain, 269–270
Poliomyelitis, esophageal motility disorders in, 215
Polymyositis, esophageal motility disorders in, 215–216
Postoperative ileus, prokinetic agents in, 449–450
Postprandial distention, gas syndromes and, 521–522
Pouchitis, after Kock pouch procedure, 104
PP (pancreatic polypeptide), 172, 390
Prednisolone, in Crohn's disease, 29–30
in inflammatory bowel disease, with antibiotics, 53
in ulcerative colitis, 24–28
Pregnancy, gastroesophageal reflux in, 287
inflammatory bowel disease in, corticosteroids in, 30
immunosuppressive therapy in, 67–68
sulfasalazine in, 9
Pro-opiomelanocortin, 166–167
Proctectomy, mucosal, in Crohn's colitis, with colectomy and ileoanal anastomosis, 122
Proctitis, corticosteroids in, 26
Proctocolectomy, in Crohn's colitis, 121
in inflammatory bowel disease, cancer risk and, 91
in ulcerative colitis, with continent ileostomy, 102–104
with permanent ileostomy, 100–101
Proctocolitis, immunosuppressive agents in, 64–65
Prodynorphin, 166–167
Proenkephalin, 166–167
Proglumide, as cholecystokinin antagonist, 762
cancer growth and, 780
Prokinetic agents, **437–457**
action of, 438–442
in constipation, 450–452
in gastroesophageal reflux, 305, 442–447
in gastroparesis, 447–449
in intestinal motility disorders, 449–452
in postoperative ileus, 449–450
uses of, 437–438
Prostaglandins, analogues of, in gastric acid hypersecretion, 855
synthesis of, sulfasalazine effects on, 5–6
Prosthesis, in gastroesophageal reflux, 308
Protease inhibitor II, cholecystokinin release and, 766–767
Protein, in acute pancreatitis, 535
in liver disease, 636–637
loss of, in inflammatory bowel disease, 569
normal absorption of, 469–470
Proton pump blockade, in gastroesophageal reflux, 304–305
Pulmonary disease, in gastroesophageal reflux, 325–328
Putrescine, in colorectal cancer, 785
PYY (peptide YY), 709–712

Radiography, small-bowel, in malabsorption identification, 479
Radiotherapy, in carcinoid tumors, 890–891
in islet cell carcinoma, 928
Ranson's prognostic criteria, in acute pancreatitis, 534
Rantidine, in gastric acid hypersecretion, 850–851, 856
Raynaud's phenomenon, in sulfasalazine therapy, 12
Recirculating intestinal loops, in short bowel syndrome treatment, 610–611
Refrobutin, in Crohn's disease, 54

Regurgitation, in achalasia, 224, 226
in functional gastroesophageal reflux, 316–320
Resection, in Crohn's disease, 115–116
Rifampin, in Crohn's disease, 54
Rigiflex achalasia dilator, 243
Riley-Day syndrome, esophageal disorders in, 213

Salicylates. See also *Aminosalicylic acid.*
in inflammatory bowel disease, oral, **43–50**
coated forms of, 45, 47
topical, **35–42**
maintenance regimen for, 40–41
relapse rate and, 39–41
treatment duration in, 38–40
with sulfasalazine, 38
Sandifer's syndrome, in gastroesophageal reflux, 320
SASP. See *Sulfasalazine.*
Satiety. See under *Cholecystokinin, actions of.*
Schilling test, in malabsorption identification, 476–477
Scintigraphy, in biliary tract motility disorders, 429
in carcinoid tumors, 875–880
in gastroesophageal reflux, 297–298, 300–301
Scleroderma, gastroesophageal reflux in, 287–288
small intestine motility disorders in, 412
Secretin, 166
actions of, 703–704
distribution of, 703
gastrin release and, 701–702
historical aspects of, 702–703
in diagnostic tests, 704
in exocrine pancreatic functional assessment, 477–478
release of, 703
structure of, 703
Selenium, deficiency of, in chronic pancreatitis, 554
in inflammatory bowel disease, 554
Serotonin, in carcinoid tumors, 873–874
Serum tests, in malabsorption identification, 472
calcium, 473
carotene, 472
fecal fat, 474–475
folate, 473
iron, 474
vitamin B_{12}, 473
Short bowel syndrome, nutritional support in, **589–601**
diarrhea management, 594
enteral feedings, 596–597
fluid and electrolyte replacement, 594
oral feeding, 594–595
parenteral nutrition, 597–598
prevention of, 614–615
steatorrhea and, 503–507
surgical therapy of, **603–617**
approaches to, 604
artificial enteric sphincters in, 609–610
early, 603–605
enteral feedings in, 604–605
intestinal interpositions in, 606–608
intestinal lengthening procedures in, 608
late, 605–611
parenteral nutrition in, 603–604
recirculating intestinal loops in, 610–611
Small intestine, biopsy of, in malabsorption identification, 480–481
culture of, in malabsorption identification, 479–480
gastric emptying receptors of, 362–365
motility disorders of, **405–424**
bacterial toxins in, 411
diagnosis of, 418
gastric surgery and, 409
in amyloidosis, 412, 414
in autonomic neuropathy, 414
in brain disease, 415–416
in dermatomyositis, 412
in diabetes mellitus, 413–414
in drug-induced neuropathy, 415
in dystrophia myotonica, 412
in enteric nervous system disease, 416
in hollow visceral myopathy, 412–413
in hypersensitivity, 417–418
in muscarinic receptor failure, 415
in neurofibromatosis, 414
in nonspecific diarrhea, 417
in orthostatic hypotension, 415
in pandysautonomia, 415
in paraneoplastic neuropathy, 414–415
in peripheral neuropathy, 413–415
in selective cholinergic dysautonomia, 415
in spinal cord injury, 415
in systemic sclerosis, 412
in tumor-associated diarrhea, 418
irritable bowel syndrome, 416–417
myopathic, 412–413
neuropathic, 413–416
obstruction, 411
prokinetic agents in, 449–450
structural diseases, 409–412
superior mesenteric artery syndrome, 411–412
treatment of, 418–419
motor activity of, **375–404**, 405–406
autonomic control of, 382–383

Small intestine *(Continued)*
central nervous system control of, 382–383, 389–390
chemical control of, 386–387
electrical control activity in, 377, 379, 381
enteric nerves in, 384–386, 391–393
giant migrating contractions, 396–398
in vomiting, 395–396, 418
individual migrating contractions, 388
individual phasic contractions, 375–387
migrating clustered contractions, 393–394
migrating motor complexes, 388–389
myogenic control of, 377, 379, 381
neural control of, 381–382
organized contractions, 388–394
peptide release in, 390–391
rapidly migrating contractions, 388
retrograde giant contractions, 395–396
special propulsive contractions, 394–398
obstruction of, motility disorders after, 411
pseudo-obstruction of, 416
prokinetic agents in, 450
resection of, nutritional management after, 504–506
steatorrhea caused by, 504
SMS 201–995. See *Octreotide.*
Somatostatin, actions of, 715–716, 899
analogues of (SMS 201–995), cancer growth and, 784
distribution of, 714–715, 899
in islet cell tumor treatment, 899–900
in small intestine motor activity, 390
release of, 715
structure of, 714
versus octreotide, 899–901
Somatostatin–14, in carcinoid syndrome, 886
Somatostatin cells, hyperplasia of, 682
tumors of, 682
Somatostatinoma syndrome, in octreotide therapy, 912
Sorbitol, irritable bowel syndrome and, 515
Spermine/spermidine, in colorectal cancer, 785
Sphincter of Oddi, manometry of, 427–429
normal function of, 426–427
Sphincterotomy, in biliary tract motility disorders, 432
Spinal cord injury, small intestine motility disorders in, 415
Steatorrhea, causes of, colon resection in, 504
ileal resection in, 503–504
jejunal resection in, 503
small bowel resection in, 504
celiac disease and, 500–502
definition of, 485
dietary treatment of, **485–512**
cholestyramine, 495
enteral support, 489–491
fat restriction, 488–490
general concepts in, 486–488
in cystic fibrosis, 498–500
in pancreatic disease, 495–498
in short bowel syndrome, 504–506
medium-chain triglycerides in, 491–494
micronutrient support in, 494–495
parenteral support in, 494
hyperoxaluria and, 489
in chronic pancreatitis, weight loss in, 549–550
in malabsorption, 467
in octreotide therapy, 912
in short bowel syndrome, 503–507
symptoms of, 485–486
Stoma, in ileostomy, continent type, 102–103
leakage from, 104
problems with, 100–101
proper placement of, 100
Stomach, argyrophil carcinoid tumors of, 683–684
cancer of, autocrine growth factors in, 785–786
peptides effects on, 779–780
carcinogenesis in, peptides and, 778
MEN effects on, 687–688
Streptozocin, in glucagonoma, 837
in insulinoma, 843
in islet cell carcinoma, 924–926
Stress, gastric emptying and, 368
Strictureplasty, in Crohn's disease, 116–117, 120
Substance K, 167
Substance P, 167, 169, 387
actions of, 717–718
distribution of, 717
in carcinoid syndrome flushing, 883
release of, 717
structure of, 717
Sucralfate, in gastroesophageal reflux, 302
Sulfasalazine, aminosalicylic acid moiety of. See *Aminosalicylic acid.*
in inflammatory bowel disease, **1–20**, 43–44, 47–48, 51–52, 61–62, 64–65
adverse effects of, 10–12
arachidonic acid metabolism and, 4–7
contraindications to, 14
desensitization to, 12–13
dosages for, 14–15
in desensitization, 13
drug interactions of, 10
immunosuppressive activity of, 4
in children, 9–10
in initial treatment, 7
in lactation, 9
in maintenance treatment, 7–9

in pregnancy, 9
intolerance to, 12–14
mode of action of, 4–7
pharmacokinetics of, 1–4
prostaglandin synthesis and, 5–6
with aminosalicylic acid, 38, 40
uses of, 9
Sulpiride, in constipation, 451
Superior mesenteric artery syndrome, small intestine motility disorders and, 411–412
Surgery. See also specific procedure, eg, *Colectomy; Proctocolectomy.*
in Crohn's disease. See under *Crohn's disease.*
in toxic megacolon, 107–108
in ulcerative colitis. See under *Ulcerative colitis.*
Swallowing, disorders of. See *Esophagus, motility disorders of.*
inhibition of, 190, 204
normal, 200–204. See also *Esophagus, motor function of.*
pain in, 259–260
Swallowing center, innervation of, 181–182
Sydenham's chorea, esophageal motility disorders in, 215

Tachykinin peptides, 167, 169
Thromboembolism, in glucagonoma, 835
Tixocortol, in ulcerative colitis, 25–26
Total parenteral nutrition, hepatobiliary abnormalities with. See under *Hepatobiliary abnormalities.*
in Crohn's disease, before surgery, 118–119
preoperative, 118–119
in fulminant colitis, 79
in inflammatory bowel disease, 131, 133, 136, 139, 141–143
Toxic megacolon, in inflammatory bowel disease, **73–82**
clinical characteristics of, 74–76
complications of, 77–78
diagnosis of, 77
incidence of, 73
laboratory results in, 76–77
pathology of, 78
prognosis of, 80
surgery rate in, 75
treatment of, 78–79, 107–108
Trace elements. See also specific elements eg, *Copper; Zinc.*
deficiencies of, in inflammatory bowel disease, **579–587**
Transforming growth factor, cancer growth and, 785–786
Transplantation, intestinal, in short bowel syndrome, 614
Trasylol, cholecystokinin release and, 764, 766
Trazodone, in esophageal pain, 269
Triolein, labeled, in malabsorption breath test, 479
Trypanosomiasis, achalasia in, 236
Trypsin, as cholecystokinin inhibitor, 763–764
Tryptophan, in cholecystokinin release, 763, 766
Tubericidin, in islet cell carcinoma, 926
Tumors, endocrine. See *Endocrine tumors.*

Ulcerative colitis, aminosalicylic acid in, 36–38
cancer risk in, 83–94
corticosteroids in, **21–28**
in chronic disease, 28
in mild disease, 26–27
in moderate disease, 27
in proctitis, 26
in severe disease, 27
maintenance with, 28
prognosis and, 28
topical administration of, 24–26
types of, 22–24
immunosuppressive agents in, 57–59, 63–68
salicylates in, oral, 43–48
sulfasalazine in, 7–8, 14–15, 38, 40
action of, 4–5
metabolism of, 3
surgery in, **99–110**
colectomy, versus corticosteroid treatment, 27
with ileal pouch formation and sphincter anastomosis, 104–107
with ileorectal anastomosis, 101–102
proctocolectomy, with continent ileostomy, 102–104
with permanent ileostomy, 100–101
total parenteral nutrition in, 131, 575–576
vancomycin in, 52
ileostomy, 102–104
with permanent ileostomy, 100–101
total parenteral nutrition in, 131, 575–576
vancomycin in, 52–53
Urinary tract complications, in Crohn's disease, 118
Urolithiasis, after Crohn's disease surgery, 123–124

Vagotomy, achalasia after, 237
parietal cell (highly selective), in Zollinger-Ellison syndrome, 859–860

Vagotomy *(Continued)*
small intestine motility disorders after, 409
Vancomycin, in inflammatory bowel disease, 52–53
Vascular occlusion treatment, in islet cell carcinoma, 927–928
Vasoactive intestinal peptide, 166
actions of, 705
carcinogenesis and, 779
distribution of, 704
in achalasia, 226–227
in gastroesophageal reflux, 278
inflammatory bowel disease and, 145
release of, 704–705
structure of, 704
tumors secreting. See *VIPoma.*
Vasoactive intestinal polypeptide, cancer growth and, 784
Vasopressin, cholecystokinin release and, 765
Verapamil, in esophageal pain, 269
Verner-Morrison syndrome, small intestine motility disorders in, 418
VIP. See *Vasoactive intestinal peptide.*
VIPoma, distribution of, 820
medical management of, 819–820
octreotide in, 905–906
surgical management of, 819–820
symptoms of, 819
with MEN–1 syndrome, 820–822
Viral infection, small intestine motility disorders in, 413
Vitamin(s), deficiency of, in chronic pancreatitis, 551–554
in inflammatory bowel disease, 580
in acute pancreatitis, 537
Vitamin B_{12}, deficiency of, in chronic pancreatitis, 552–553
low serum levels of, 473
replacement therapy with, after Crohn's disease surgery, 123
Vomiting, in functional gastroesophageal reflux, 316–320
mechanisms of, 368–369
small intestine motor activity in, 395–396, 418
Von Recklinghausen's disease, small intestine motility disorders in, 414

Weight loss, diabetes and, 548–549
in chronic pancreatitis, 544–551
in glucagonoma, 835
in inflammatory bowel disease, 579
in steatorrhea, 485
Witzel achalasia dilator, 243

Xylose, labeled, in malabsorption breath test, 478–479
Xylose absorption test, in malabsorption identification, 475–476

YY peptide, 709–712

Zenker's diverticulum, 213
Zinc, deficiency of, in chronic pancreatitis, 553
in inflammatory bowel disease, 581–583
Zollinger-Ellison syndrome. See also *Gastrinoma.*
gastric hypersecretion management in. See under *Gastric acid hypersecretion.*
gastrinoma distribution in, 686
MEN–1 syndrome with, 820–822
parathyroidectomy in, 860–861